Boston Scientific resumes AVANT GUARD trial in drug-naïve persistent AFib patients

BOSTON SCIENTIFIC CORP

AVANT GUARD trial resumed after assessment of observations and DMC input.
Study targets new population of drug-naïve patients with persistent atrial fibrillation.
No financial impact or patient enrollment numbers disclosed.

item 7.01

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-24-000075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.